EMERA INC
EMANYSETrading Snapshot
- Day Range
- $47.80 β $48.57
- 52-Week Range
- $46.87 β $55.49
- Volume
- $2.73B
- Avg Volume
- $2.04B
- Shares Outstanding
- 305.9M
- Next Earnings
- Dec 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $8.30B
- Last Q Revenue
- $1.98B
- P/E Ratio
- 21.5
- P/S Ratio
- 2.6x
- EPS (TTM)
- $3.39
- Dividend Yield
- 4.29%
- Dilution (1yr)
- +2.0%
Why Investors Own EMA
- βHigh-growth profile β revenue up +4.5% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EMERA INC
EMA
StockOtter Β· stockotter.spaceAbout EMERA INC
Emera Incorporated, an energy and services company, invests in generation, transmission, and distribution of electricity in the United States, Canada, Barbados, and the Bahamas. The company operates through Florida Electric Utility, Canadian Electric Utilities, Gas Utilities and Infrastructure, Other Electric Utilities, and Other segments. It is involved in the purchase, transmission, distribution, and sale of natural gas; and physical energy marketing, trading, and other energy asset management activities. The company was incorporated in 1998 and is headquartered in Halifax, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Emera Incorporated (TSE:EMA) Given Consensus Rating of βModerate Buyβ by Brokerages
Shares of Emera Incorporated (TSE: EMA - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat.com reports. Three research analysts have
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics Holdings Inc. (the Γ’ΒΒCompanyΓ’ΒΒ, Γ’ΒΒArcturusΓ’ΒΒ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA
Engineers Gate Manager LP lifted its position in shares of eMagin Corporation (NYSE: EMA) by 182.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissio
Extreme Delivers Industry's First Proactive, Context-Aware AI Agent for Networking
[url="]Extreme Networks[/url], Inc. (NASDAQ: EXTR) today announced the general availability of [url="]Extreme Agent ONEΓ’ΒΒ’ Coworker[/url], the next generation o
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia PR Newswire
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing